id: NEW:alpha2_adrenergic_agonist_treatment_to_smoking_current
name: Alpha-2 Adrenergic Agonist Treatment (Clonidine) â†’ Current Smoking Status
from_node:
  node_id: NEW:alpha2_adrenergic_agonist_treatment
  node_name: Alpha-2 Adrenergic Agonist Treatment (Clonidine)
to_node:
  node_id: smoking_current
  node_name: Current Smoking Status
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Clonidine, an alpha-2 adrenergic agonist, is administered as pharmacotherapy for tobacco use
  disorder'
- 'Step 2: Alpha-2 agonist action reduces noradrenergic activity in the locus coeruleus and central nervous
  system'
- 'Step 3: Reduced noradrenergic signaling attenuates withdrawal symptoms and stress-related craving'
- 'Step 4: Decreased withdrawal severity and craving improves ability to maintain smoking abstinence'
- 'Step 5: Increased smoking cessation rates reduce current smoking prevalence'
evidence:
  quality_rating: A
  n_studies: 10
  primary_citation: 'P. Vanderkam et al. 2020. "Effectiveness of drugs acting on adrenergic receptors
    in the treatment for tobacco or alcohol use disorders: systematic review and meta-analysis." https://doi.org/10.1111/add.15265'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 10 tobacco studies
  - Studies identified through PUBMED, EMBASE, Cochrane Central Register of Controlled Trials
  - Randomized controlled trials with adult patients meeting DSM-5 criteria
  doi: 10.1111/add.15265
  citation_verified: true
  needs_manual_review: true
  citation_issues:
  - Primary citation doesn't match verified citation from literature search
last_updated: '2025-12-06'
version: '2.0'
description: Clonidine, an alpha-2 adrenergic agonist, significantly increases smoking abstinence rates
  by 39% compared to placebo or other comparators. This effect operates through modulation of the noradrenaline
  system, which plays a key role in nicotine withdrawal and craving.
quantitative_effects:
  effect_size:
    value: 1.39
    type: relative_risk
    ci_lower: 1.04
    ci_upper: 1.84
moderators:
- name: treatment_duration
  direction: strengthens
  strength: moderate
  description: Study required minimum one month intervention with three months follow-up, suggesting duration
    may influence effectiveness
structural_competency:
  equity_implications: Access to evidence-based pharmacotherapy for tobacco use disorder represents a
    healthcare access issue. Populations with limited healthcare access, insurance coverage, or prescription
    drug coverage may face barriers to accessing clonidine treatment. Smoking prevalence disparities across
    socioeconomic groups could be partially addressed through improved access to pharmacotherapy options
    beyond traditional nicotine replacement.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.353511'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
